Trial: 201909180

A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Phase

II

Principal Investigator

Dipersio, John

Disease Site

Lymphoid Leukemia; Multiple Myeloma; Non-Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov